Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 20/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.71 |
| ▸ | AR | P10275 | 4/20 | 0.71 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3991080 | 0.86 | PGR (0.82) | PGRNR3C2ARNR3C1 | |
| SCHEMBL3986429 | 0.85 | PGR (1.00) | PGRNR3C2ARNR3C1 | |
| SCHEMBL3985084 | 0.83 | PGR (0.84) | PGRNR3C2ARNR3C1 | |
| SCHEMBL3984864 | 0.83 | PGR (1.00) | PGRNR3C2ARNR3C1 | |
| SCHEMBL17471460 | 0.83 | PGR (0.71) | PGRNR3C2ARNR3C1 | |
| SCHEMBL61743 | 0.83 | PGR (1.00) | PGRNR3C2ARNR3C1 | |
| SCHEMBL3988402 | 0.83 | PGR (0.77) | PGRNR3C2ARNR3C1 | |
| SCHEMBL3989440 | 0.83 | PGR (1.00) | PGRNR3C2ARNR3C1 | |
| SCHEMBL3988776 | 0.82 | PGR (1.00) | PGRNR3C2ARNR3C1 | |
| SCHEMBL3985181 | 0.82 | PGR (1.00) | PGRNR3C2ARNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113964-A1 | 7-Aryl 1,5-Dihydro-4,1-Benzoxazepin-2(3H)-One Derivatives and Their Use As Progesterone Receptor Modulators | WYETH (US) | 2008-05-15 | — | — | US | claimed |
| US-20050215539-A1 | 7-aryl 1,5-dihydro-4, 1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators | WYETH (US) | 2005-09-29 | — | — | US | claimed |
| US-7598237-B2 | 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators | WYETH (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080139530-A1 | 7-Aryl 1,5-Dihydro-4,1-Benzoxazepin-2(3H)-One Derivatives And Their Use As Progesterone Receptor Modulators | WYETH (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080113964-A1 | 7-Aryl 1,5-Dihydro-4,1-Benzoxazepin-2(3H)-One Derivatives and Their Use As Progesterone Receptor Modulators | WYETH (US) | 2008-05-15 | — | — | US | disclosed |
| US-7323455-B2 | 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators | WYETH (US) | 2008-01-29 | — | — | US | disclosed |
| US-20050215539-A1 | 7-aryl 1,5-dihydro-4, 1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators | WYETH (US) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113964-A1 | 7-Aryl 1,5-Dihydro-4,1-Benzoxazepin-2(3H)-One Derivatives and Their Use As Progesterone Receptor Modulators | PGR, GPER1, PGRMC2 | PGR 1/4885NR3C2 6/4885AR 43/4885 |
| US-20080139530-A1 | 7-Aryl 1,5-Dihydro-4,1-Benzoxazepin-2(3H)-One Derivatives And Their Use As Progesterone Receptor Modulators | PGR, GPER1, PGRMC2 | PGR 1/4885NR3C2 6/4885AR 43/4885 |
| US-20050215539-A1 | 7-aryl 1,5-dihydro-4, 1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators | PGR, GPER1, PGRMC2 | PGR 1/4885NR3C2 6/4885AR 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.